Fanregratinib · ATLED
Small molecule
Also known as HMPL-453
Evidence outlook
Approved: Advanced, metastatic or unresectable intrahepatic cholangiocarcinoma with FGFR2 fusion or... (CN)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
Also approved (1)
- Advanced, metastatic or unresectable intrahepatic cholangiocarcinoma with FGFR2 fusion or rearrangement after prior systemic therapy (conditional approval)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
No registered studies for this indication.
Competitive landscape
Other FGFR1/2/3 drugs
1 other tracked programme targets this mechanism, 1 of them ahead of this one.
This drug's own stage for Cholangiocarcinoma: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Fanregratinib (ATLED): this drug | Stage not on record | Small molecule | FGFR1/2/3 | not yet graded | No reviewed efficacy summary in this indication | |
| Futibatinib (Lytgobi) | Approved | Small molecule | FGFR (FGFR1/2/3/4) | Weak signal | No reviewed efficacy summary in this indication | |
| Lirafugratinib (Lyrfigtu) | Approved | Small molecule | FGFR2 | not yet graded | No reviewed efficacy summary in this indication | |
| Pemigatinib (Pemazyre) | Approved | Small molecule | FGFR1/2/3 | Weak signal | No reviewed efficacy summary in this indication | |
| Zenocutuzumab (Bizengri) | Approved | Multispecific antibody | HER2; HER3 (blocks NRG1 binding to HER3) | not yet graded | No reviewed efficacy summary in this indication | |
| Tinengotinib | Phase 3 | Small molecule | Aurora A/B kinase (with secondary FGFR1/2/3, VEGFR1, JAK1/2, CSF1R inhibition) | Weak signal | Featured results are safety only in this race | |
| Toripalimab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Crelosidenib | Phase 1 | Small molecule | Mutant IDH1 and IDH2 | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent